| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
As an amino acid derivative, Tosyl-L-arginine does not have a defined primary drug target. Its role is as a synthetic intermediate in peptide synthesis and as a research tool in enzymatic assays. Arginine residues are important for protein-protein interactions and enzymatic catalysis. However, the tosylated derivative itself is not known to directly bind to or modulate any specific protein. Its primary utility is in protecting the guanidino group during peptide synthesis.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity of Tosyl-L-arginine is primarily related to its role as a protected amino acid derivative. It may be used as a substrate or inhibitor for enzymes that recognize arginine, such as trypsin or other proteases. However, its specific in vitro activity has not been extensively characterized beyond its utility in peptide synthesis and enzymatic assays. Amino acid derivatives like this one have been commercially used as ergogenic supplements, but this is not its primary application. |
| ln Vivo |
There is no reported in vivo activity for Tosyl-L-arginine as it is not a drug substance. The compound is used primarily as a research chemical and a synthetic intermediate. It is not administered to animals for pharmacological evaluation. Its role is confined to the laboratory, where it serves as a tool for peptide synthesis and enzymatic studies.
|
| Enzyme Assay |
In vitro enzyme assays could use Tosyl-L-arginine as a substrate for proteases such as trypsin. In such an assay, the compound is incubated with the enzyme, and the cleavage of the tosyl-arginine bond is monitored using HPLC or a colorimetric method. This assay is commonly used to measure protease activity or to screen for inhibitors.
|
| Cell Assay |
Cell-based assays for Tosyl-L-arginine are not typical, as it is primarily used as a reagent for peptide synthesis. However, it could be used in cell-based assays to study the effects of arginine analogs on cellular processes. For example, it could be used to investigate the role of arginine in nitric oxide synthesis or other metabolic pathways.
|
| Animal Protocol |
In vivo animal experiments are not performed with Tosyl-L-arginine itself. The compound is a research chemical used exclusively for peptide synthesis and enzymatic studies. It is not administered to animals for pharmacological evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Tosyl-L-arginine have not been characterized as it is not a drug candidate. The compound is intended for research use only. As a synthetic intermediate, its ADME profile is not relevant. The compound is typically stored at room temperature or -20°C.
|
| Toxicity/Toxicokinetics |
The toxicity profile has not been extensively studied. The compound is classified for research use only and is not intended for human or veterinary use. Standard laboratory safety precautions should be followed. Specific toxicological information is not available.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Tosyl-L-arginine is a tosylated arginine derivative used as a building block in peptide synthesis and as a research tool in enzymatic assays. It is not a drug and has no approved therapeutic indications. The compound is commercially available for research purposes only.
|
| Molecular Formula |
C13H20N4O4S
|
|---|---|
| Molecular Weight |
328.39
|
| Exact Mass |
328.12
|
| CAS # |
1159-15-5
|
| PubChem CID |
52501
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
591.3±60.0 °C at 760 mmHg
|
| Melting Point |
81-103ºC
|
| Flash Point |
311.4±32.9 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
0.81
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
22
|
| Complexity |
489
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCN=C(N)N)C(=O)O
|
| InChi Key |
KFNRNFXZFIRNEO-NSHDSACASA-N
|
| InChi Code |
InChI=1S/C13H20N4O4S/c1-9-4-6-10(7-5-9)22(20,21)17-11(12(18)19)3-2-8-16-13(14)15/h4-7,11,17H,2-3,8H2,1H3,(H,18,19)(H4,14,15,16)/t11-/m0/s1
|
| Chemical Name |
(2S)-5-(diaminomethylideneamino)-2-[(4-methylphenyl)sulfonylamino]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0452 mL | 15.2258 mL | 30.4516 mL | |
| 5 mM | 0.6090 mL | 3.0452 mL | 6.0903 mL | |
| 10 mM | 0.3045 mL | 1.5226 mL | 3.0452 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
